Gene therapies (including CAR T) could add $45 billion to US healthcare costs over the next five years, a CVS health report finds.

Sitting Down With... Miguel Forte, Chief Executive Officer at Bone Therapeutics, Belgium, to discuss advanced medicine.

UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house.

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.

Ravi Nalliah explains his journey from biochemistry and molecular biology student, to chartered accountant, to supply chain CDMO founder.

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.

We announce a new Special Series of articles devoted to advanced medicine.

Jane Osbourn talks about the potential of the UK's cell and gene therapy space.

The UK’s CGT Catapult has played a significant role in building the strong advanced therapy ecosystem in the UK, the largest outside the USA.

Glad tidings of progress and confidence this (conference) season! But let’s not dismiss the emerging skills challenge as “humbug.”